Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MLTX

MoonLake Immunotherapeutics

Dec 26 • 09:36AM ET

53.41

Dollar change +0.74
Percentage change 1.40	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: AMGN VRTX REGN ALNY BIIB BMRN GILD INCY SRPT BLUE

| Held by: VHT SBIO MSSM NUSC ESML ONEQ VT GURU FHLC TMSL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.29	Insider Own	16.22%	Shs Outstand	63.05M	Perf Week	2.22%
Market Cap	3.41B	Forward P/E	-	EPS next Y	-2.71	Insider Trans	-17.17%	Shs Float	52.84M	Perf Month	-1.40%
Income	-80.77M	PEG	-	EPS next Q	-0.60	Inst Own	95.19%	Short Float	15.21%	Perf Quarter	3.97%
Sales	0.00M	P/S	-	EPS this Y	-141.19%	Inst Trans	-2.15%	Short Ratio	29.05	Perf Half Y	28.11%
Book/sh	7.74	P/B	6.90	EPS next Y	-53.68%	ROA	-15.86%	Short Interest	8.04M	Perf Year	-13.21%
Cash/sh	7.73	P/C	6.91	EPS next 5Y	-	ROE	-17.69%	52W Range	37.55 - 64.98	Perf YTD	-11.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-16.48%	52W High	-17.81%	Beta	1.31
Dividend TTM	-	Quick Ratio	25.51	Sales past 5Y	0.00%	Gross Margin	-	52W Low	42.24%	ATR (14)	2.56
Dividend Ex-Date	-	Current Ratio	25.51	EPS Y/Y TTM	-36.77%	Oper. Margin	-	RSI (14)	52.76	Volatility	5.92% 5.03%
Employees	50	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.27	Target Price	77.31
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-219.53%	Payout	-	Rel Volume	0.23	Prev Close	52.67
Sales Surprise	-	EPS Surprise	-28.59%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	276.73K	Price	53.41
SMA20	0.27%	SMA50	4.67%	SMA200	14.09%	Trades		Volume	4,147	Change	1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-24	Resumed	Wedbush	Outperform	$92 → $73
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform	$104
Apr-02-24	Initiated	Goldman	Neutral	$62
Feb-15-24	Initiated	Wolfe Research	Outperform	$77
Dec-08-23	Initiated	Citigroup	Buy	$72
Nov-02-23	Initiated	Stifel	Buy	$74
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy	$76
Jun-15-23	Initiated	Barclays	Equal Weight	$28
May-01-23	Initiated	Guggenheim	Buy	$51
Mar-22-23	Initiated	Wedbush	Outperform	$33
Mar-09-23	Initiated	BTIG Research	Buy	$36
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight	$23
Feb-02-23	Initiated	Bryan Garnier	Buy	$22
Nov-11-22	Initiated	Jefferies	Buy	$16
Aug-25-22	Initiated	SVB Leerink	Outperform	$17
Jul-21-22	Initiated	H.C. Wainwright	Buy	$28
Jul-07-22	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-13-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Nov-07-24 07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-08-24 09:11PM	Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics (GuruFocus.com)
Sep-24-24 11:55PM	Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? (Insider Monkey) -6.36%
Sep-23-24 02:44AM	MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
07:00AM	Loading…
Sep-09-24 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 (GlobeNewswire)
Aug-27-24 08:21PM	MoonLake Immunotherapeutics (MLTX): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 08:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 (GlobeNewswire)
Jun-10-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis (GlobeNewswire)
May-16-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
May-07-24 09:02PM	MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes (GuruFocus.com)
01:53PM	MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024 (InvestorPlace)
10:15AM	MoonLake Immunotherapeutics Q1 Net Loss Widens (MT Newswires)
08:00AM	MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-10-24 07:00AM	MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions (GlobeNewswire)
04:25PM	Loading…
Mar-11-24 04:25PM	MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test (Investor's Business Daily)
Mar-10-24 12:00PM	MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day (GlobeNewswire)
Mar-04-24 08:00AM	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 12:38AM	Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) (GuruFocus.com) +5.56%
Feb-29-24 08:00AM	MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 (GlobeNewswire) -15.09%
Feb-26-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS) (GlobeNewswire)
Feb-20-24 11:44PM	Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com) -7.88%
Jan-11-24 09:55AM	Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade (Zacks)
Jan-10-24 08:42AM	Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 03:01PM	CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com)
Nov-14-23 12:13PM	MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses (GuruFocus.com)
08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 04:03PM	Why Former Highflier MoonLake Plummeted 29% After A Recent Run (Investor's Business Daily) -29.11% +15.98%
09:46AM	Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug (Investor's Business Daily)
Nov-05-23 11:00AM	MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis (GlobeNewswire)
10:33AM	Loading…
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:30PM	MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst (Benzinga) +10.72% -5.20%
04:04PM	Why Top-Notch MoonLake Surged 11% And Almost Broke Out (Investor's Business Daily)
10:41AM	Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout (Investor's Business Daily)
Oct-15-23 09:03AM	MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (GlobeNewswire)
Oct-11-23 10:15AM	MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress (GlobeNewswire) -7.06%
Oct-04-23 07:01AM	Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-18-23 05:09PM	These 7 Stocks Are Outperforming Nvidia In 2023 (Investor's Business Daily)
Sep-13-23 09:45AM	ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54% (Zacks)
Sep-12-23 04:07PM	The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10% (Investor's Business Daily) +9.88%
11:40AM	Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday (Motley Fool)
Sep-06-23 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 (GlobeNewswire)
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -6.32%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:53AM	Palantir downgraded, Shopify upgraded: Wall Street's top analyst calls (The Fly)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-16-23 03:12PM	15 Best Performing Stocks in the Last 3 Months (Insider Monkey)
Aug-15-23 07:00AM	Get In on This Skin Disease Drug Before Big Pharma Does (The Wall Street Journal)
Aug-10-23 07:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-25-23 08:00AM	MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts (GlobeNewswire)
Jul-14-23 03:38PM	Exclusive-MoonLake Immunotherapeutics explores sale-sources (Reuters) +8.39%
Jul-03-23 09:45AM	MoonLake Immunotherapeutics' (NASDAQ:MLTX) high hedge funds ownership speaks for itself as stock continues to impress, up 11% over last week (Simply Wall St.)
Jun-29-23 02:41PM	Why MoonLake Immunotherapeutics Stock Skyrocketed This Week (Motley Fool)
Jun-28-23 05:00AM	MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares (GlobeNewswire)
Jun-27-23 06:56PM	Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today (Motley Fool) +12.71%
Jun-26-23 04:07PM	Why Mutual Fund Darling And Top 1% Stock MoonLake Just Catapulted To A Record (Investor's Business Daily) +77.55%
04:01PM	MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
02:36PM	Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday (Motley Fool)
09:01AM	Lucid Stock Moved Into the Fast Lane, but This Nasdaq Biotech Was Monday's Big Winner (Motley Fool)
Jun-25-23 09:00AM	MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa (GlobeNewswire)
May-26-23 08:50AM	MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-12-23 07:45AM	MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-11-23 08:32AM	Why MoonLake (MLTX) Might Surprise This Earnings Season (Zacks) -5.45%
May-10-23 08:50AM	Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep going (Zacks)
May-03-23 06:45AM	MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply (GlobeNewswire) +7.55%
Apr-24-23 08:50AM	MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +10.08%
Apr-19-23 08:16AM	MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today (GlobeNewswire)
Apr-05-23 12:00PM	What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock (Zacks) +6.84%
Mar-20-23 07:45AM	MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update (GlobeNewswire) -7.87%
Feb-14-23 01:02PM	Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path (Benzinga) +8.16%
Feb-02-23 08:00AM	MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
Dec-14-22 08:00AM	MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis (GlobeNewswire)
Nov-14-22 08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update (GlobeNewswire)
Sep-26-22 10:57AM	FDA Clears MoonLake's Nanobody Study For Arthritis Patients (Benzinga)
08:00AM	MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Jul-26-22 08:00AM	MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH (GlobeNewswire) +13.31%
Jul-25-22 10:11AM	Do Insiders Own Lots Of Shares In MoonLake Immunotherapeutics (NASDAQ:MLTX)? (Simply Wall St.)
May-12-22 07:00AM	MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BVF PARTNERS L P/IL	Director	Oct 04 '24	Sale	50.00	2,000,000	100,003,200	1,287,768	Oct 08 06:50 PM
Sturge Simon	Director	Oct 04 '24	Sale	53.72	171,000	9,186,120	171,980	Oct 08 04:01 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 27 '24	Sale	55.00	62,810	3,454,550	3,043,619	Feb 29 07:56 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 28 '24	Sale	55.00	56,065	3,083,575	2,987,554	Feb 29 07:56 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 29 '24	Sale	55.89	4,740	264,919	2,982,814	Feb 29 07:56 PM
Reich Kristian	Chief Scientific Officer	Feb 28 '24	Sale	55.00	31,910	1,755,050	2,925,573	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 27 '24	Sale	55.00	29,491	1,622,005	2,957,483	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 27 '24	Sale	55.00	29,431	1,618,705	70,071	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 28 '24	Sale	55.00	28,090	1,544,950	41,981	Feb 29 07:53 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 21 '24	Sale	55.27	1,125	62,179	3,106,429	Feb 23 04:48 PM
Reich Kristian	Chief Scientific Officer	Feb 20 '24	Sale	57.45	10,000	574,500	2,987,483	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 20 '24	Sale	57.43	10,000	574,300	100,071	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 21 '24	Sale	55.30	569	31,466	99,502	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 21 '24	Sale	55.31	509	28,153	2,986,974	Feb 22 06:32 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 15 '24	Sale	60.18	20,000	1,203,600	3,147,554	Feb 20 06:36 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 16 '24	Sale	60.15	20,000	1,203,000	3,127,554	Feb 20 06:36 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 20 '24	Sale	57.44	20,000	1,148,800	3,107,554	Feb 20 06:36 PM
Reich Kristian	Chief Scientific Officer	Feb 14 '24	Sale	62.43	10,000	624,300	130,071	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 14 '24	Sale	62.42	10,000	624,200	3,017,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 15 '24	Sale	60.17	10,000	601,700	3,007,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 15 '24	Sale	60.16	10,000	601,600	120,071	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 16 '24	Sale	60.15	10,000	601,500	2,997,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 16 '24	Sale	60.15	10,000	601,500	110,071	Feb 16 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MLTX

MoonLake Immunotherapeutics

Upgrade your FINVIZ experience